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General discussion
This thesis described the study of determinants of cognitive function at old age and 
was divided into two parts. The first part focused on the reversal of associations of 
classical risk factors for dementia and mortality with increasing age. We put emphasis 
on the influence of age on the association between total cholesterol levels and 
cognitive function and on the influence of structural brain damage on the association 
between blood pressure and cognitive function. Furthermore, we tried to gain insight 
in the temporal relation of longitudinal changes of these risk factors with cognitive 
function, underlying disease, and mortality. The second part of this thesis focused 
on both phenotypic and genetic variation in apolipoprotein E in relation to cognitive 
function and on the biological mechanisms behind these relations. 
In this chapter the main findings of this thesis are summarized and discussed. Some 
methodological issues that apply to the studies in this thesis will be addressed, 
thereby discussing study designs and ways of analyzing. Furthermore, our findings 
will be evaluated in the light of possible clinical implications and some suggestions 
for further research are made. 
Main findings
Traditional metabolic risk factors, cognitive function and mortality in late-life
In chapter 1 we give an overview of current literature on the influence of age on 
the association between total cholesterol levels and cognitive function. Although 
high cholesterol levels in midlife associate with an increased risk of dementia in 
late-life, this association attenuates with increasing age. In fact, in old age high 
cholesterol levels have even been shown to associate with better cognitive function 
and lower risk of dementia and also with a lower risk of cardiovascular disease. 
Statin treatment, although shown to be protective for cardiovascular events in old 
age, has not been shown to decrease the risk of dementia or cognitive impairment 
in old age, following results from randomized controlled trials. Low cholesterol 
levels in late-life may reflect underlying disease, thereby explaining the reversal of 
associations with increasing age. 
Also blood pressure has been shown to have age-specific associations with dementia. 
Hypertension in midlife has clearly been shown to be a risk factor for dementia 1,2, 
but in late-life hypertension is no longer a risk factor for dementia, and the presence 
of dementia has even been shown to associate with low blood pressure 3-5. In chapter 
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2 we describe that, in a population of patients with memory complaints who were 
referred to a memory outpatient clinic, high blood pressure associated with better 
cognitive function in patients with structural brain damage, whereas this association 
was absent in patients with medium or low structural brain damage. The most likely 
explanation for these fi ndings is that high blood pressure is needed for maintaining 
adequate brain perfusion and subsequently adequate brain function, but only in 
subjects who have functional or structural changes in cerebral vasculature, which 
has been observed in Alzheimer’s disease brains 6-8. 
In accordance with the before mentioned results, evidence has accumulated that in 
late-life, well-known classical risk factors, such as obesity, hypercholesterolemia, 
and hypertension, are no risk factors for dementia anymore. Moreover, in late-
life obesity, high cholesterol levels, and high blood pressure have been associated 
with lower mortality 9-11, whereas these risk factors impose an increased mortality 
risk when present in midlife 12-14. With increasing age, declines in values of these 
classical risk factors have been observed 15-17, and these declines have been linked 
to declines in cognitive function and dementia 18-20. In chapter 3 and chapter 4 
we used repetitive measurements in late-life of classical risk factors to give better 
insight in the dynamics of classical risk factors and their relation with changes in 
cognitive function and with mortality. We showed that declines in global cognitive 
function preceded declines in total cholesterol levels, HDL cholesterol levels, and 
blood pressure in following years, and not vice versa. Moreover, mortality was 
associated with larger annual declines in body mass index, total cholesterol levels, 
HDL cholesterol levels, and blood pressure. Principal component analysis showed 
clustering in dynamics of the classical risk factors in one component, which strongly 
associated with cancer mortality, in a profi le that is suggestive of an underlying 
wasting state. 
The results from these studies suggest that late-life declines in classical risk factors are, 
at least in part, the result of underlying disease, amongst which dementia processes. 
This gives a plausible explanation for why these classical risk factors have reversed 
associations with dementia and mortality in old age. For blood pressure however, 
some other mechanism also seems to play a role in the reversal of associations with 
cognitive function. We provide support for the theory that high blood pressure in late 
life may be needed to maintain cognitive function by functioning as a compensatory 
reaction to overcome the consequences of an aging vasculature. 
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Apolipoprotein E variation, cognitive function in late-life, and risk of dementia 
Variation in the APOE gene is the strongest genetic risk factor for late onset 
Alzheimer’s disease. Carriers of the ε4-allele are at an increased risk of Alzheimer’s 
disease, whereas ε2-allele carriers might be protected 21-23. Despite years of research, 
the exact biological mechanism explaining for this association is unclear. Besides 
the qualitative variation in the APOE gene, quantitative variation in apoE, such as 
variation in plasma apoE levels, has also been suggested to play a role in the dementia 
process, although previous studies have shown opposing results 24-28. In chapter 5 
and chapter 6 we investigated the association of plasma apoE levels with cognitive 
function and risk of late onset Alzheimer’s disease in two different populations. In 
chapter 5 we showed that high plasma apoE levels, when measured at baseline in 
a population based cohort of 85-year old subjects, associated with worse cognitive 
function at baseline and during five year follow-up in ε3ε3- and ε3ε4-carriers, but 
not in ε2ε3 carriers. In chapter 6 we showed that, using an alternative approach by 
using a family study design, generally healthy middle-aged offspring with a parental 
history of Alzheimer’s disease had lower plasma apoE levels than offspring without 
such a history. Although contradicting at first sight, the difference in outcome between 
the two studies might be explained by the presence of underlying disease in old 
age. At middle age, higher apoE levels may be protective for late onset Alzheimer’s 
disease, due to the protective effects of apoE on atherosclerosis, oxidative damage, 
and inflammation 29,30. In late-life however, high plasma apoE levels may also be the 
result of decreased clearance, or the result of up regulation of apoE expression as an 
adaptive response to systemic damage. This way, high apoE levels in late-life may 
reflect ill health, whereas high apoE levels in midlife could be the mere result of 
an increased innate expression capacity. In support of this reasoning is that plasma 
apoE levels are higher in old age compared to middle age, and high plasma apoE 
levels have been shown to associate with an increased mortality in the 85 year old 
population 31. 
Besides the role of apoE variation in lipid metabolism, lipid peroxidation scavenging, 
and inflammation regulation, animal studies have pointed in the direction of apoE 
influencing calcium homeostasis in neuronal cells 32-37. These studies have shown apoE 
to increase intracellular calcium levels in an isoform specific (apoE4>apoE3>apoE2) 
and dose dependent manner by the influx of extracellular calcium. The influx of 
calcium and the increased intracellular calcium levels resulted in neuronal cell 
death, which exemplifies the calcium hypothesis of Alzheimer’s disease 38. In our 
population of 85 year olds, high serum calcium levels have been shown to associate 
with worse cognitive function 39. In chapter 7 we showed that high serum calcium 
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levels were strongly associated with worse cognitive function in ε3ε4 carriers, to a 
lesser extent in ε3ε3 carriers, but not in ε2ε3 carriers. These observational fi ndings 
are suggestive for a similar biological mechanism in humans, as was observed in 
experimental animal studies. ApoE4 may facilitate calcium infl ux in neuronal cells 
stronger than apoE3 and apoE2, which could lead to increased neuronal cell death 
and subsequent decreased cognitive function. Mechanistically, compared to apoE3 
and apoE2, apoE4 could facilitate calcium infl ux through an increased permeability 
of neuronal cellular membranes, or an increased beta-amyloid deposition, with 
subsequent dysregulation of calcium homeostasis. 
Methodological issues on study design and analyses
The data presented in this thesis were derived from a variety of studies with different 
cross-sectional and longitudinal designs. Generally, data coming from cross-sectional 
studies are viewed as inferior to data coming from longitudinal studies, because 
they would not allow drawing conclusions on causality. However, by analyzing the 
data in different strata in one study and by using a family study design in the other 
cross-sectional study, we were able to make some remarks on possible causality. The 
longitudinal data in this thesis provided the opportunity to study temporal relations 
between changes in classical risk factors and changes in cognitive function. 
In chapter 2 we studied cross-sectional data on the association between blood 
pressure and cognitive function in patients visiting our memory outpatient clinic. 
By analyzing the association between blood pressure and cognitive function in 
strata of structural brain damage severity we were able to disentangle the effects 
of blood pressure on cognitive function from the effects of structural brain damage 
on cognitive function. This allowed us to formulate a plausible hypothesis on the 
biological background, but proof of causality must come from longitudinal studies. 
The family study design, which was used in chapter 6 in this thesis, is the exception 
to the rule that cross-sectional studies do not allow for causal illation. A family study 
design offers the opportunity to study risk factors years before the onset of the studied 
disease, and is therefore not hampered by reversed causation caused by underlying 
disease. Under the assumption that the studied disease is heritable, children from 
subjects with the disease and children from subjects without the disease are selected, 
with the disease being absent in the children. This results in a classical case-control 
design, with a case group containing subjects at increased risk of the disease and 
a control group containing subjects not at an increased risk of the disease. By 
comparing levels or occurrence of suspected risk factors between the two groups, 
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conclusions can be drawn on factors that increase the risk of disease.
The Leiden 85-Plus Study, a prospective population based study, was used in 
chapter 3, chapter 4, chapter 6, and chapter 7 in this thesis. In two chapters the 
longitudinal design of the Leiden 85-Plus Study offered the opportunity to study the 
effect of late-life changes in classical risk factors on both mortality and changes in 
cognitive function. In the latter case, the longitudinal design was essential to study 
whether changes in cognitive function preceded or followed changes in the risk 
factors. The five year follow-up period was split in two time-frames, and annual 
changes in classical risk factors and global cognitive function were calculated for 
each time-frame. This allowed us to make careful conclusions on causality. 
Although associations between changes in classical risk factors and mortality could 
causally only be interpreted in one direction, with mortality being the endpoint of 
study, it remains questionable whether changes itself would directly lead to mortality 
or are simply the consequence of underlying disease leading to mortality. To test 
for co-occurrence and patterns in changes of classical risk factors, which could be 
suggestive of underlying processes leading to the changes, we performed principal 
component analysis in chapter 4. Principal component analysis is often used to 
discover and summarize patterns of intercorrelations among a set of variables 40. 
By performing principal component analysis the highest correlations of the input 
variables with one another are grouped, thereby assuming that a common underlying 
dimension (component) influences each variable separately. The possibility to 
operationalize the component as a new variable offered the opportunity to test for 
the influence of components on specific causes of death. This gave further support 
for speculations on which underlying process may drive the changes in classical risk 
factors.  
Clinical implications
In this thesis we provide data that suggest that in late-life, classical risk factors 
of mortality and dementia are subject to change over time, and these changes 
are associated with cognitive decline and mortality. Declines in body mass 
index, total cholesterol levels, and blood pressure are shown to associate with an 
increased mortality risk. This raises the question whether treatment of obesity, 
hypercholesterolemia, and hypertension in old age may in itself have detrimental 
effects, since treatment results in declines in these risk factors. However, randomized 
controlled trials in elderly populations have shown that statin and antihypertensive 
treatment both decrease mortality risk 41,42. This strongly suggests that medication 
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induced declines in classical risk factors represent a different biological mechanism 
than observational declines. The latter are likely the result of underlying disease, and 
therefore associate with increased mortality. Question remains whether treatment 
as a preventive measure is warranted in the general elderly population, or whether 
treatment should be reserved for specifi c groups. In the HYVET-study for instance, 
only subjects with high systolic blood pressure were selected to participate in the 
study 43. This selection criterion resulted in a study sample that represented a fairly 
healthy subgroup of the general population. Whether further reducing classical risk 
factors by treatment with statins and antihypertensives in subjects who already have 
low cholesterol levels and low blood pressure is highly questionable, especially 
when these are the result of strong declines in previous years. Furthermore, although 
shown to be protective for cardiovascular events and mortality, statin treatment and 
antihypertensive treatment have not been shown to decrease the risk of dementia and 
cognitive decline in old age 41,44,45. Moreover, data presented in this thesis point to 
a possible benefi cial effect of high blood pressure on cognitive function in patients 
with structural brain damage. This could imply that antihypertensive treatment of 
patients with structural brain damage may have detrimental effects on cognitive 
function. Possibly, discontinuation of antihypertensive treatment may be warranted 
in these patients, in order to improve brain perfusion and subsequently improve brain 
function. Although tempting, due to the observational character of our study, strong 
recommendations on the discontinuation of antihypertensive treatment in patients 
with structural brain damage cannot be made yet. Despite these uncertainties it is 
clear that there is no evidence for statin and antihypertensive treatment in old age for 
the prevention of dementia. 
Following our results that low plasma apoE levels in midlife may increase the risk of 
late onset Alzheimer’s disease, logical reasoning may point towards benefi cial effects 
of increasing plasma apoE levels. Treatment strategies for humans that are focused 
on infl uencing apoE levels have mainly been hypothetical up till now, but some 
support for these treatments has come forward from animal studies. Most animal 
studies have focused at infl uencing intracerebral apoE, instead of systemic apoE. 
Some benefi cial effects have been shown of intrathecal administration of apoE after 
cerebral ischemia 46. Other studies have demonstrated improvement in histological 
and functional outcomes in preclinical models of subarachnoid hemorrhage, multiple 
sclerosis, and traumatic brain injury after the administration of an apoE-mimetic 
drug 47. One small sized pilot clinical trial in a cohort of mild-to-moderate Alzheimer 
disease subjects showed that administration of probucol for 6 months revealed a 
concomitant stabilization of symptoms on dementia scales 48. Probucol is an old 
cholesterol-lowering drug, which was shown to induce apoE synthesis and secretion 
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in cortical and hippocampal regions in rats and mice. Given the highly experimental 
stage at which these trials are performed, it is very questionable whether systemic 
administration or the stimulation of endogenous apoE production could offer benefit 
in humans. 
Future research
One of the main findings in this thesis is that high blood pressure could be beneficial 
for brain function in subjects with structural brain damage, possibly through the 
maintenance of brain perfusion. However, to clarify the biological mechanism behind 
this assumption, the effect of variation in blood pressure on cerebral blood flow and 
cerebral perfusion should be studied in more detail in relation to age and structural 
brain damage. The final step would be to design trials to study the potential beneficial 
effects of increasing blood pressure in patient populations with structural brain 
damage and cognitive impairment, for instance by discontinuing antihypertensive 
treatment. Designing these trials and selecting patients for these studies should be 
done with utmost care, since the possible beneficial effect on cognitive function 
should be weighed against the possible harmful effect on survival and cardiovascular 
events.
Another intriguing finding of this thesis is that high serum calcium levels were 
associated with worse cognitive function in ε3ε4 carriers, to a lesser extent in 
ε3ε3 carriers, but not in ε2ε3 carriers. The negative association between serum 
calcium levels and cognitive function may explain why treatment with calcium 
antagonists has been shown to protect against dementia and cognitive decline 49,50, 
whereas treatment with other antihypertensive medication has not been shown to be 
beneficial. Following the results in this thesis, it would be interesting to test whether 
the effect of calcium antagonist treatment is also APOE genotype specific. Future 
pharmacogenetic studies could provide information and ultimately lead to APOE 
genotype specific treatment and prevention regimes.
In conclusion, this thesis clearly shows that classical risk factors of dementia 
and mortality are subject to change with increasing age. Whereas obesity, 
hypercholesterolemia, and hypertension are detrimental in midlife, in late-life 
declines in body mass index, cholesterol levels, and blood pressure, all being likely 
the result of underlying disease, associate with cognitive decline and mortality. 
Besides these classical risk factors, plasma apoE levels also seem to be subject to 
changes with increasing age, supposedly under the influence of underlying disease. 
In midlife, low plasma apoE levels associate with an increased risk of dementia, 
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whereas in late-life high plasma apoE levels seem to refl ect underlying disease 
and therefore associate with worse cognitive function. In general, conclusions 
from studies investigating risk factors of dementia and mortality in middle-aged 
populations can not be extrapolated to old-aged populations. With increasing age, 
the prevalence of multi-morbidity strongly increases and this heavily infl uences 
the associations of risk factors with dementia and mortality. Whether treatment of 
classical risk factors in late-life is benefi cial or whether treatment effect might be 
dependent on underlying disease should receive more attention in future research. 
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